UNSPSC 51112519: Metamelfalan

This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B30XBE7S2, chemically known as l-phenylalanine, 3-(bis(2-chloroethyl)amino)- (9ci) but more generally known as metamelfalan, which bears US NIH Compound Identifier 14152. European Medicines Agency schedules Metamelfalan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08806MIG.

UNSPSC 51112519 Metamelfalan is a Commodity code covering pharmaceutical products, specifically a chemotherapy agent used in cancer treatment protocols. State and local governments procure this drug primarily through their Medicaid programs, state employee health plans, and corrections departments for inmate medical care. The work involves sourcing, pricing negotiation, and supply chain management for controlled pharmaceutical products subject to FDA approval, state pharmacy board oversight, and managed care formulary restrictions. Issuing bodies include state health and human services departments (the primary buyers), Medicaid agencies, corrections departments, and large municipal health systems. The procurement approach typically involves pharmacy benefit managers, group purchasing organizations, or direct-to-manufacturer contracting arrangements, with vendors required to meet DEA registration, state pharmacy licensing, and pharmaceutical distribution compliance requirements.

Geographic activity centers on Texas, where the Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI (HHS0017013) explores vendors' capacity to establish direct relationships between the state pharmacy benefit program and manufacturers to improve prescription fulfillment and cost management, specifically soliciting experience with direct contracting for self-insured employers and government health plans, flexibility on net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI functions as preliminary market intelligence gathering rather than a formal competitive solicitation; the state indicated it will use vendor responses to develop detailed procurement specifications and pricing models for a subsequent formal RFP. No award value or budget range was identified in the RFI materials at the time of posting.